Welcome to LookChem.com Sign In|Join Free
  • or
(4R)-4-[(5S,7R,8S,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid is a complex steroid compound that belongs to the pentanoic acid family. It features a cyclopenta[a]phenanthren structure with hydroxy and methyl functional groups at specific stereocenters, which may contribute to its potential biological activity. Due to its structural similarity to natural steroids, (4R)-4-[(5S,7R,8S,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid is likely involved in hormone regulation and metabolic processes, making it a candidate for further research into its physiological effects and applications.

28083-34-3

Post Buying Request

28083-34-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

28083-34-3 Usage

Uses

Used in Pharmaceutical Industry:
(4R)-4-[(5S,7R,8S,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid is used as a potential therapeutic agent for hormone-related conditions due to its structural resemblance to natural steroids and its potential to interact with hormone receptors. This interaction may modulate hormonal balance and treat various disorders associated with hormonal imbalances.
Used in Research and Development:
In the field of medicinal chemistry and biological research, (4R)-4-[(5S,7R,8S,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid serves as a valuable research tool for studying the mechanisms of hormone action and developing new drugs targeting hormone receptors. Its unique structure allows scientists to investigate its binding properties and effects on cellular processes, potentially leading to the discovery of novel therapeutic agents.

Check Digit Verification of cas no

The CAS Registry Mumber 28083-34-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,0,8 and 3 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 28083-34:
(7*2)+(6*8)+(5*0)+(4*8)+(3*3)+(2*3)+(1*4)=113
113 % 10 = 3
So 28083-34-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H40O3/c1-15(7-10-21(26)27)17-8-9-18-22-19(11-13-24(17,18)3)23(2)12-5-4-6-16(23)14-20(22)25/h15-20,22,25H,4-14H2,1-3H3,(H,26,27)/t15-,16+,17-,18+,19+,20-,22+,23+,24-/m1/s1

28083-34-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 7alpha-Hydroxy-5beta-cholan-24-oic acid

1.2 Other means of identification

Product number -
Other names 7α-Hydroxy-5β-cholan-24-saeure

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:28083-34-3 SDS

28083-34-3Relevant academic research and scientific papers

Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands

Festa, Carmen,Renga, Barbara,D'Amore, Claudio,Sepe, Valentina,Finamore, Claudia,De Marino, Simona,Carino, Adriana,Cipriani, Sabrina,Monti, Maria Chiara,Zampella, Angela,Fiorucci, Stefano

, p. 8477 - 8495 (2015/01/09)

Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1, two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids often target both receptor families, the development of selective ligands has been proven difficult, exposing patients to side effects linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic bile acid derivatives obtained by modifications on the cholane scaffold. The pharmacological characterization of this library led to the discovery of 7α-hydroxy-5β-cholan-24-sulfate (7), 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 26), and 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in the treatment of FXR and GP-BAR1 mediated disorders.

Improved enantioselectivity in the epoxidation of cinnamic acid derivatives with dioxiranes from keto bile acids

Bortolini, Olga,Fantin, Giancarlo,Fogagnolo, Marco,Forlani, Roberto,Maietti, Silvia,Pedrini, Paola

, p. 5802 - 5806 (2007/10/03)

The asymmetric epoxidation of substituted cinnamic acids has been obtained in the presence of different keto bile acid derivatives as optically active carbonyl inducers and Oxone as oxygen source. Predominant or almost exclusive formation of both enantiomeric epoxides is obtained (ee up to 95%) depending on the specific substitution at carbons C(7) and C(12) of the bile acid.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 28083-34-3